Company intelligence / Profile preview

Ophthalytics

Ownership: Private
Development stage: Other

Overview

The company has developed an AI-powered diagnostic system for early detection of diabetic retinopathy and other vision-threatening eye diseases. The technology autonomously analyzes retinal images to identify disease features. The product/platform was under FDA clearance as of the latest available information. No clinical trial results are reported since it’s a diagnostics/software device.

Therapeutic areas: Ophthalmology
Modalities: DeviceSoftware
Industry: Digital Health Medical Devices

Beyond the preview

Go deeper on Ophthalytics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ophthalytics.

Explore the full profile